Breast Cancer in Seniors: Navigating Long-Term Care & Life.

The rising incidence of breast cancer in older adults – nearly half of the 310,000 annual US cases occur in those 65 and older – is forcing a critical re-evaluation of treatment protocols. A recent review in Current Breast Cancer Reports underscores that age isn’t simply a number; it’s a key determinant of survivorship challenges, demanding a shift towards personalized, geriatric-informed care. This isn’t merely about extending lifespans, but preserving quality of life and independence for a rapidly growing patient population.

Deep Dive: The Complexities of Aging and Breast Cancer

The increasing number of older adults diagnosed with breast cancer isn’t solely a demographic shift. Improved screening practices and increased longevity contribute, but the review highlights a crucial point: older patients often present with more comorbidities – cardiovascular disease and obesity being the most common (affecting 40-75% of patients). While these comorbidities don’t necessarily *increase* post-treatment, their development is strongly linked to worse mortality outcomes. This underscores the need to move beyond simply treating the cancer and address the patient’s overall health status.

Beyond comorbidities, the review details significant impacts on physical and cognitive function. Up to 87% of older patients report musculoskeletal impacts post-surgery (particularly after mastectomy and axillary dissection), while treatment-related bone loss affects up to 80%, increasing fracture risk. The cognitive effects – often referred to as “chemotherapy brain” – are also substantial, with survivors nearly twice as likely to report problems three years post-diagnosis, especially with hormone therapy. The concept of ‘frailty’ – affecting roughly 23% of those over 70 – is particularly concerning, as it’s a strong predictor of reduced survival, functional decline, and increased chemotherapy toxicity.

Forward Look: Towards a Geriatric-Informed Oncology

The publication of this review isn’t an isolated event. It’s part of a growing movement within oncology to prioritize geriatric principles. We can expect to see increased adoption of Comprehensive and Practical Geriatric Assessments (GAs) in clinical practice. ASCO and NCCN already support their use, but implementation has been slow. The key will be integrating these assessments into existing workflows – the “Practical GA” is a step in the right direction. Expect to see more emphasis on prehabilitation (exercise and nutritional optimization *before* treatment) to mitigate functional decline.

However, overcoming clinician reluctance to de-escalate treatment will be a major hurdle. Qualitative data suggests doctors are hesitant to reduce the intensity of therapy, even when evidence supports it. Increased use of shared decision-making tools and patient education will be critical to address this. Furthermore, research into age-specific systemic therapy regimens is needed to optimize efficacy while minimizing toxicity. Finally, addressing the under-treatment of older patients – particularly those over 75 – with guideline-concordant systemic therapy will require targeted interventions and a focus on equitable access to care. The future of breast cancer treatment for older adults isn’t about doing *more*; it’s about doing what’s *right*, tailored to the individual’s physiological age and goals.

Reference: Morton CR, Lorentzen EH, Minami CA. Survivorship issues in older adults with breast cancer. Curr Breast Cancer Rep. 2025;17(20):10.1007/s12609-025-00586-1. doi:10.1007/s12609-025-00586-1